What is ISoP?
The International Society of Pharmacovigilance (ISoP) is an international non-profit scientific organisation, which aims to foster Pharmacovigilance both scientifically and educationally, and enhance all aspects of the safe and proper use of medicines, in all countries. more…
ISoP Seminar
ISoP Seminar 2019
Boston, USA,
2-3 December 2019
Intelligent Automation in Pharmacovigilance.
ISoP-UMC
7th ISoP-UMC Training
Guangzhou, China,
11-12 November 2019
Pharmacovigilance systems in China: Moving to the next step.
ISoP 2019
Annual Meeting
Bogota, Colombia
26-29 October 2019
New opportunities for new generations.
ISoP Chapters Activities
Israel Meeting
03-04 June 2019
READ MORE
Africa Chapter Elections
04-16 October 2019
READ MORE
Middle East Meeting
17-18 November 2019
READ MORE
ISoP Training
Mid Year Training
Moscow, Russia,
27-29 April 2020
Moving Pharmacovigilance Forward in the Eurasian Economic Union (EAEU)
REGISTER INTEREST
ISoP ETP
Education Training Programme
Education Training Programme
A primary objective of ISoP is to promote the safest use of drugs through contributing to appropriate education.
ISoP 2020
Annual Meeting
Muscat, Oman
12-15 October 2020
Integrated Pharmacovigilance for Safer Patients
READ MORE
What’s New
ISoP Advisory Board 2019-2022
CIOMS Establishes Annual Award for Medical Students
‘Manual de Buenas Prácticas de Farmacovigilancia’
Role and strategy of ISoP in global pharmacovigilance
Article published in Int. Journal of Clinical Pharmacy
Updated ISoP Privacy Policy
In line with the new General Data Protection Regulation (GDPR)
ISoP Latest
President of ISoP
I am honoured and delighted to have been elected as President of ISoP – as announced on 28th October 2019 at our Annual General Meeting in Bogota – and am especially proud to be the first woman to ever hold this role in our professional society.
Mira Harrison‐Woolrych
President – International Society of Pharmacoviliance
Drug Safety
ISoP Official Journal
Drug Safety is the premier international journal covering the disciplines of pharmacovigilance, pharmacoepidemiology, benefit-risk assessment and risk management.